SCHEMBL10197527

SCHEMBL10197527

CC1COc2cc(Br)ccc2N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.40
BLM P54132 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
ADRA2A P08913 1/20 0.37
PNMT P11086 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
AHR P35869 3/20 0.35
PBRM1 Q86U86 1/20 0.34
ALOX5 P09917 1/20 0.34
CYP19A1 P11511 1/20 0.34
CA2 P00918 1/20 0.34
HCRTR2 O43614 1/20 0.33
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
BRD4 O60885 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34463405 1.00 AR (0.40) ARBLMLMNAMAPTHTT
SCHEMBL3790279 0.86 AR (0.40) ARBLMLMNAMAPTHTT
SCHEMBL9845271 0.81 AR (0.41) ARBLMMAPTCYP19A1CA2
SCHEMBL9035064 0.79 AR (0.43) ARALOX5CYP19A1CA2HCRTR2
SCHEMBL20798244 0.79 KDM4E (0.41) ARAHRALOX5CYP19A1CA2
SCHEMBL23920054 0.79 KDM4E (0.41) ARAHRALOX5CYP19A1CA2
SCHEMBL9035075 0.79 AR (0.43) ARALOX5CYP19A1CA2HCRTR2
SCHEMBL10494909 0.79 AR (0.40) ARBLMLMNAMAPTCYP19A1
SCHEMBL23920052 0.79 KDM4E (0.41) ARAHRALOX5CYP19A1CA2
SCHEMBL8641161 0.79 BRD4 (0.44) ARBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed
WO-2010107768-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT AR 2382/4885BLM 4386/4885LMNA 3371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.